2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1329

Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Abstract Number: 436

Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis
Abstract Number: 1569

Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Abstract Number: 1716

Poor-Prognosis Factors of Systemic Vasculitides with Gastrointestinal Involvement: Data from a Large Retrospective Study
Abstract Number: 1343

Pop a Pill or Give Myself a Shot? Patient Perspectives of Disease-modifying Anti-rheumatic Drug (DMARD) Choice for Rheumatoid Arthritis (RA)
Abstract Number: 2077

Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia and the Fallacy of the Variance Explained
Abstract Number: 2549

Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials
Abstract Number: 1463

Positive Rate of Small Intestinal Bacterial Overgrowth Test (SIBO) Was Significant Correlations to Disease Activity of Primary Sjogren’s Syndrome (pSS)
Abstract Number: 1411

Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy
Abstract Number: 2261

Post Traumatic Stress Disorder in Patients with Rheumatoid Arthritis
Abstract Number: 2372

Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry
Abstract Number: 1346

Post-Traumatic Stress Disorder, Depression, Anxiety and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis
Abstract Number: 73

Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome
Abstract Number: 1774

Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis
Abstract Number: 649

Potentially Reversible Associations with Fatigue in SLE Patients – Results from a Single-centre Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].